Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 179 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Modulation Clear all
Terminated Not applicable Interventional Results available

Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain

NCT01466764
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Anakinra, Normal Saline
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 21, 2026, 10:29 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

NCT00121953
View directory record Official record
Conditions
Endometriosis
Interventions
Rosiglitazone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 21, 2026, 10:29 PM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Modulation Of Airway Reactivity With Chronic Mechanical Strain

NCT02396849
View directory record Official record
Conditions
Asthma
Interventions
Continuous Positive Airway Pressure (CPAP), Continuous Positive Airway Pressure (CPAP) Sham
Device
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 10:29 PM EDT
Terminated Phase 1 Interventional

Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma

NCT01816555
View directory record Official record
Conditions
Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 21, 2026, 10:29 PM EDT
Recruiting Phase 1 Interventional

GAIP ASD Research Study

NCT07622316
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
Biological · Drug
Lead sponsor
Greater Atlanta Integrative Pediatrics
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Roswell, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 10:29 PM EDT
Not yet recruiting Phase 2 Interventional

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

NCT07815704
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
Interventions
Standard of Care + atorvastatin, Standard of Care (SOC)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 10:29 PM EDT
Terminated Phase 1 Interventional

Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease

NCT01046773
View directory record Official record
Conditions
Crohn's Disease, Vitamin D Deficiency
Interventions
Cholecalciferol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Helminth ova
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 21, 2026, 10:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions

NCT06950060
View directory record Official record
Conditions
Stroke, Chronic, Aging, Cognitive Decline, Motor Dysfunction, Neuroplasticity
Interventions
High intensity cycling, Low-intensity cycling, Health education session, Moderate Intensity Aerobic Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 10:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

NCT02514083
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Fludarabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Other · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

Immunomodulation Following Transfusion

NCT00810810
View directory record Official record
Conditions
Blood Component Transfusion
Interventions
Standard blood components, Leukoreduced blood components, Leukoreduced and irradiated
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 21, 2026, 10:29 PM EDT
Recruiting Phase 3 Interventional

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes

NCT04011020
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
10 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

NCT00002759
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclosporine, irinotecan hydrochloride, phenobarbital
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 21, 2026, 10:29 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

NCT05480657
View directory record Official record
Conditions
Brittle Type 1 Diabetes Mellitus
Interventions
AT-1501 IV Infusion, Isolated cadaveric islet cells
Biological
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 21, 2026, 10:29 PM EDT
Terminated Early Phase 1 Interventional

Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

NCT03241719
View directory record Official record
Conditions
Amputation, Traumatic, Amputation;Traumatic;Old, Face Injury, Face; Deformity, Abdominal Wall Defect
Interventions
IL-2
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics

NCT00607230
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BCG, Saline
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 21, 2026, 10:29 PM EDT
Suspended Phase 1 Interventional

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

NCT02333162
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
Interventions
Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 10:29 PM EDT
Terminated No phase listed Observational

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

NCT01114256
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Head and Neck Cancers, Non-Hodgkin Lymphoma, Colorectal Adenocarcinoma
Interventions
FNA Biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
View directory record Official record
Conditions
Multiple Myeloma, Primary Amyloidosis
Interventions
Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 21, 2026, 10:29 PM EDT
Terminated Not applicable Interventional

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

NCT03889093
View directory record Official record
Conditions
Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Interventions
Yttrium-90
Other
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 21, 2026, 10:29 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

"Immunomodulation in GWI (Phlebotomy)"

NCT04058275
View directory record Official record
Conditions
Gulf War Illness
Interventions
Draw blood (phlebotomy, 83 ml)
Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 21, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00002945
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
25 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 21, 2026, 10:29 PM EDT